Objective To investigate the difference in the clinicopathologic features, prognosis and expression of CARMA1 gene between CD10, Bcl6 and MUM1 postive and negative expression group in diffuse large B cell lymphoma (DLBCL) cases. Methods Twenty-seven cases with DLBCL, which were CD10, Bcl6 and MUM1 postive or negative expression. The clinicopathological data of these cases were collected. CARMA1 mRNA level was detected by RT-PCR method. Follow-up and statistical analysis were done. Results Compared with CD10, Bcl6 and MUM1 negative expression group, patients in positive expression group had higher expression of Ki67, later staging, shorter survival time. CARMA1 mRNA level had an increasing trend in positive group. Conclusions DLBCL cases expressing CD10, Bcl6, MUM1 have a poor clinical course and prognosis. Over expression of CARMA1 maybe associate with the pathogenesis and progress in DLBCL with CD10, Bcl6, MUM1 postive expression.%目的 比较CD10、Bc16和MUM1全阳性和全阴性表达的弥漫大B细胞淋巴瘤(DLBCL)病例的临床病理特征、预后和CARMA1基因表达的差异.方法 用HE和免疫组化染色筛选出27例CD10、Bc16和MUM1全阳性或全阴性表达的DLBCL病例,检测肿瘤细胞Ki67表达水平,收集其临床病理资料并随访,RT-PCR技术检测肿瘤组织中CARMA1 mRNA表达并进行半定量分析.结果 与CD10、Bc16和MUM1全阴性组比较,全阳性组病例Ki67表达率升高,临床分期较晚,中位生存时间缩短,CARMA1 mRNA表达水平有升高的趋势.结论 CD10、Bc16和MUM1全阳性表达的DLBCL病例的临床过程和预后较全阴性表达组差,CARMA1可能在全阳性DLBCL中存在过表达并参与病变发生发展过程.
展开▼
